Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2003
10/01/2003CN1445225A Intermediate for preparing benzothiophene amide derivate
10/01/2003CN1444990A Strengthened ganoderma lucidum for possible immunoprophylaxis and immunotherapy of cancers and related diseases as well as its preparing method
10/01/2003CN1122719C Modified biological material
10/01/2003CN1122662C Arylsulfonylamino hydroxamic acid derivatives
10/01/2003CN1122513C Use of compound in medicine for preparation of inhibiting pathological conditions
09/2003
09/30/2003US6627769 Antiproliferative agents
09/30/2003US6627754 Pyrrolo[2,3-d]pyrimidine compounds
09/30/2003US6627652 Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
09/30/2003US6627647 Treating an inflammatory disease which comprises administering to a patient in need of such treatment a compound for autoimmune diseases
09/30/2003US6627646 Dissolving norastemizole in a solvent at a temperature between 70 degrees C. and 110 degrees C.; adding an amount of nonsolvent sufficient to initiate crystallization at a temperature above 70 degrees C.;stirring
09/30/2003US6627640 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
09/30/2003US6627638 Viricides, anticarcinogneic agents
09/30/2003US6627637 I kappa B kinase inhibitors for treating various disorders including arthritis
09/30/2003US6627633 The compounds also are potent inhibitors of human cellular proliferation. As such, the compounds constitute pharmaceutical compositions with a pharmaceutically acceptable carrier. Such compounds are useful in inhibiting cellular
09/30/2003US6627629 Useful for the treatment or prevention of asthma and other allergic diseases.
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627605 Polynucleotides which encode them, and methods for their use. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention further provides methods for diagnosing or treating disorders with
09/30/2003US6627405 53BP2 complexes
09/30/2003US6627200 Utilization of CD 137 in order to promote the proliferation of peripheral monocytes
09/30/2003US6627195 Binding agents to CD23
09/30/2003US6627194 Activated immunoglobulin
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/25/2003WO2003078658A2 Methods for diagnosing and treating schizophrenia
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078614A2 Gntiii (udp-n-acethylglucosamine:beta-d mannoside beta (1,4)-n-acethylglucosaminy ltransferase iii) expression in plants
09/25/2003WO2003078595A2 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
09/25/2003WO2003078435A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
09/25/2003WO2003078427A1 Azolylaminoazines as inhibitors of protein kinases
09/25/2003WO2003078426A1 Azolylaminoazine as inhibitors of protein kinases
09/25/2003WO2003078421A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078419A1 N-substituted benzothiophenesulfonamide derivative
09/25/2003WO2003078416A1 Therapeutic ion channel blocking agents and methods of use thereof
09/25/2003WO2003078409A1 Carboxyoic acid compounds and drugs containing the compounds as the active ingredient
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078403A2 Derives d’aminoindazoles comme inhibiteurs de proteine-kinase
09/25/2003WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078361A1 Controlling chemical reactions by spectral chemistry and spectral conditioning
09/25/2003WO2003077947A1 Methods of modulating cd200 receptors
09/25/2003WO2003077946A1 Medicinal agent and method for curing pathologic syndrome associated to hemodyscrasia
09/25/2003WO2003077944A1 Improvements in vaccination
09/25/2003WO2003077921A1 Azinylaminoazoles as inhibitors of protein kinases
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077915A1 Use of rapamycin for inhibiting of cell death
09/25/2003WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
09/25/2003WO2003077882A2 Preparation of sterile stabilized nanodispersions
09/25/2003WO2003077881A2 Method for production of phytoalexins
09/25/2003WO2003077865A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077864A2 Methods and compositions for directing cells to target organs
09/25/2003WO2003077863A2 Method for overexpression of zwitterionic polysaccharides
09/25/2003WO2003077862A2 Potent, simplified derivatives of immunosuppressive agents
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003040313A3 Il-21 antagonists
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003035682A3 Peptides and protins binding to glu-pro motidfs, therapeutical compositions containing them and their applications
09/25/2003WO2003020219A3 Aerosolized decongestants for the treatment of sinusitis
09/25/2003WO2003013577A3 Use of il-18 inhibitors in hypersensitivity disorders
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003012078A3 Dendritic cells and the uses thereof in screening cellular targets and potential drugs
09/25/2003WO2003011855A3 Pyrazole-derived kinase inhibitors and uses thereof
09/25/2003WO2003000907A3 Improved transfection of eukaryotic cells with linear polynucleotides by electroporation
09/25/2003WO2003000709A3 Sialic acid derivatives for use as siglec inhibitors
09/25/2003WO2002094282A3 Compositions with methylprednisolone derivatives having therapeutic effect
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002064612A9 Human g-protein chemokine receptor (ccr5) hdgnr10
09/25/2003WO2002063004A3 G-protein coupled receptors
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002026982A3 Secreted human proteins
09/25/2003WO2002014489A9 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
09/25/2003WO2001093921A3 Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
09/25/2003US20030182667 Type iii allergic inflammation model animal
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181722 An immunosuppressants for treating autoimmune diseases, antiallergic agents, antitumor agents
09/25/2003US20030181706 Inflammation-associated polynucleotides
09/25/2003US20030181687 Heparanase activity neutralizing anti-heparanase monoclonal antibody
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181506 Hetercyclic carboxy compounds such as alpha-methyl-2-naphthalene-methyl 2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate used to selectively regulate induction of cytotoxic effecter macrophages
09/25/2003US20030181499 For use as anti-human immunodeficiency virus (HIV) drugs
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181471 Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders
09/25/2003US20030181457 Tertiary amides used as preferential inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase, for prophylaxis of cardiovascular and sexual disorders
09/25/2003US20030181452 Inotropic agents such as (S)-N-tert-butyloxycarbonyl-N-methyl-tyrosyl)-4-(4-nitrophenyl)-piperazine, used for preventing and/or prophylaxis of diseases associated with adenosine 5'-triphosphate
09/25/2003US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181435 Systemic lupus erythematosus therapy
09/25/2003US20030181397 Synergistic composition of bioactive fraction isolated barleria prionitis linn and a method of treatment for hepatotoxicity, immuno-deficiency and fatigue and a process thereof
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181370 H-Y antigen
09/25/2003US20030181362 Receptor
09/25/2003US20030181361 Sustained-release pharmaceutical formulations of therapeutic proteins containing carboxymethyl ether cellulose polymer and methods of manufacture and use thereof.
09/25/2003US20030181352 Substituted heterocyclic compounds
09/25/2003US20030180947 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180818 Isolated nucleic acid molecules encoding human peptidoglycan recognition protein-related proteins, referred to PGRP-K (keratinocytes), PGRP-W (wound healing) and PGRP-C (chondrosarcoma)
1 ... 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 ... 1172